JPRN-UMIN000008701已完成2 期
Multicenter phase II trial to assess clinical benefit of zoledronic acid with neo adjuvant endocrine treatment and the relationship between zoledronic acid use and gammadelta T cells for postmenopausal breast cancer. - A phase II study whether zoledronic acid with neoadjuvant endocrine therapy is more effectvely related to gammadelta T cells.
Breast Surgery, Graduate School of Medicine, Kyoto University0 个研究点目标入组 75 人开始时间: 2012年11月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)Hyperparathyroidism requires for treatment, Uncontrolled diabetes mellitus, Disease requires continuous and systemic administration of steroid hormone, Dental and/or periodontal disease which requires invasive treatment after registration. 2)Synchronous double cancer, Met asynchronous double cancer diagnosed in 5 years (excluding basal cell carcinoma, carcinoma in situ, superficial bladder cancer, neoplasms cured by endoscopic surgery)3)Prior treatament with bisphosphonates 4)Patients who have received hormone replacement therapy ( If HRP is stopped more than 7 days prior to study entry, they meet registration criteria.) 5)Hypersensitivity to contrast materials for MRI 6)Use of other investigational drugs in 28 days prior to study entry 7)Patients who are judged inappropriate for the clinical trial by doctors
研究者
相似试验
进行中（未招募）
不适用
Multicenter, phase II trial assessing the efficacy and safety of bevacizumab (Avastin®) combined to trastuzumab (Herceptin®) based chemotherapy in patients with primary inflammatory HER2+ breast cancer - BEVERLY 2Primary inflammatory HER2+ breast cancerMedDRA version: 9.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerMedDRA version: 9.1Level: LLTClassification code 10021974Term: Inflammatory breast cancerEUCTR2008-000783-16-FRROCHE SAS
尚未招募
不适用
Phase I / II, Multicenter Clinical trial to evaluate the safe dose range and confirm the effectiveness and safety of the maximum tolerated dose of Docetaxel In combination with SH003 in patients with solid tumor who are indicated for DocetaxelKCT0004770Korea University Anam Hospital110
进行中（未招募）
不适用
A multicenter phase II clinical trial assessing the efficacy of the combination of lapatinib and capecitabine in patients with non pretreated brain metastasis from HER2 positive breast cancer. - LANDSCAPEEUCTR2008-001084-10-FRFNCLCC
进行中（未招募）
1 期
Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab, gemcitabine, oxaliplatin and dexamethasone followed by Ibrutinib maitenance in patients with refractory/relapsed non-GCB diffuse large B-cell lymphoma non candidates to ASCTMedDRA version: 18.1Level: HLTClassification code 10012819Term: Diffuse large B-cell lymphomasSystem Organ Class: 100000004851diffuse large B-cell lymphomaEUCTR2015-005390-21-ESGELTAMO64
进行中（未招募）
不适用
Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab in patients with indolent clinical forms of Mantle Cell Lymphoma.Mantle Cell LyphomaMedDRA version: 18.1Level: HLTClassification code 10026798Term: Mantle cell lymphomasSystem Organ Class: 100000004851EUCTR2015-004158-17-ESGELTAMO (Grupo Cooperativo Español de Llinfoma/Trasplante Autólogo de Médula Ósea)